Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 3 for:    social anxiety cognitive behavioral therapy Stanford
Previous Study | Return to List | Next Study

Effect of Behavior Therapy on Responses to Social Stimuli in People With Social Phobia

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
James J. Gross, Stanford University
ClinicalTrials.gov Identifier:
NCT00380731
First received: September 22, 2006
Last updated: November 29, 2011
Last verified: November 2011

September 22, 2006
November 29, 2011
September 2006
August 2011   (final data collection date for primary outcome measure)
  • Liebowitz Social Anxiety Scale [ Time Frame: Measured at Months 4, 7, 10, 13, and 16 ] [ Designated as safety issue: No ]
  • fMRI BOLD response [ Time Frame: Measured at Month 4 ] [ Designated as safety issue: No ]
  • Behavioral assessment [ Time Frame: Measured at Months 4 and 16 ] [ Designated as safety issue: No ]
  • Measured at Months 4, 10, and 16: Liebowitz Social Anxiety Scale
  • Measured at Month 4: fMRI BOLD response
  • Behavioral assessments
Complete list of historical versions of study NCT00380731 on ClinicalTrials.gov Archive Site
  • Clinical Global Impression Improvement Scale [ Time Frame: Measured at Months 4 and 16 ] [ Designated as safety issue: No ]
  • Social Interaction Anxiety Scale [ Time Frame: Measured at Months 4, 10, and 16 ] [ Designated as safety issue: No ]
  • Sheehan Disability Scale [ Time Frame: Measured at Months 4, 10, and 16 ] [ Designated as safety issue: No ]
  • Quality of Life Inventory [ Time Frame: Measured at Months 4, 10, and 16 ] [ Designated as safety issue: No ]
  • Measured at Months 4, 10, and 16: Clinical Global Impression Improvement Scale
  • Social Interaction Anxiety Scale
  • Sheehan Disability Scale
  • Quality of Life Inventory
Not Provided
Not Provided
 
Effect of Behavior Therapy on Responses to Social Stimuli in People With Social Phobia
fMRI of Emotional Reactivity Cognitive Regulation and CBT for Social Phobia

This study will evaluate the effect of cognitive behavioral therapy on the brain during emotional and behavioral responses to social stimuli in people with social phobia.

Social phobia, also known as social anxiety disorder, is a common, often debilitating condition. People with social phobia experience high levels of anxiety when they participate in social situations or perform in front of others. Approximately 80% of social phobia cases occur before the age of 18, and often precede other anxiety, mood, and substance abuse or dependence disorders. Physical symptoms typically accompany the intense anxiety caused by the disorder, and may include blushing, profuse sweating, trembling, nausea, and difficulty talking. Cognitive-behavioral therapy (CBT) has been shown to be an effective treatment method for most people with social phobia. Approximately 30% of people with the disorder, however, do not respond to CBT treatment. A better understanding of the neural mechanisms underlying social phobia and CBT's effect on these mechanisms will help physicians to better predict the best treatment for different patients. This study will evaluate the effect of CBT on how the brain processes emotional and behavioral responses to social stimuli in people with social phobia.

Participants in this open-label study will be randomly assigned to either immediate or delayed treatment with CBT. Participants who are assigned to immediate CBT will attend 16 sessions of individual CBT immediately following baseline assessments. Participants assigned to the delayed treatment condition will begin attending CBT sessions approximately 5 months following baseline assessments. Outcomes will be assessed for all participants at baseline, immediately post-treatment, and at Months 5 and 10 post-treatment. An fMRI scan will be used to measure neural responses to social stimuli, and various questionnaires and scales will be used to assess anxiety symptom severity. Participants in the delayed treatment group will be assessed on one additional occasion before they begin treatment after the 5-month waiting period.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Social Phobia
Behavioral: Individual Cognitive Behavioral Therapy
CBT includes 16 weekly 60-minute individual CBT sessions for social anxiety disorder.
  • Experimental: 1
    Participants will receive immediate cognitive behavioral therapy
    Intervention: Behavioral: Individual Cognitive Behavioral Therapy
  • Experimental: 2
    Participants will receive cognitive behavioral therapy with a 16-week delayed start
    Intervention: Behavioral: Individual Cognitive Behavioral Therapy

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
124
August 2011
August 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Meets DSM-IV criteria for generalized social phobia
  • English-speaking
  • Eligible to participate in fMRI scanning
  • Willing to use an effective form of contraception throughout the study

Exclusion Criteria:

  • Currently undergoing any psychotherapy or pharmacotherapy (e.g, selective serotonin reuptake inhibitors, benzodiazepines, beta-blockers, anti-psychotics, blood thinners, thyroid hormone influencing agents, diabetic medications, or anticonvulsants)
  • History of neurological or cardiovascular disorders, brain surgery, electroconvulsive or radiation treatment, brain hemorrhage or tumor, stroke, seizures or epilepsy, diabetes, hypo- or hyperthyroidism, or head trauma with loss of consciousness for more than 5 minutes
  • Smokes cigarettes daily
  • History of or current diagnosis of schizophrenia, schizoaffective disorder, organic mental disorder, bipolar disorder, or antisocial, schizotypal, or schizoid personality disorders
  • Suicidal thoughts
  • Clinically significant and/or unstable medical disease
  • Pregnant or breastfeeding
  • Alcohol or substance abuse or dependence within the 12 months prior to study entry
  • History of or current seizure disorder (except febrile seizure disorder during childhood)
Both
21 Years to 55 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00380731
R01 MH076074, R01MH076074, DATR A3-NSS
Yes
James J. Gross, Stanford University
Stanford University
National Institute of Mental Health (NIMH)
Principal Investigator: James J. Gross, PhD Stanford University
Stanford University
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP